|Targets||p21-activated Kinases (PAKs)|
|Description||IPA-3 is a selective non-ATP competitive Pak1 inhibitor with IC50 of 2.5 μM, no inhibition to group II PAKs (PAKs 4-6).|
G‑5555, a pyridopyrimidine derivative, has been found to be a PAK1 inhibitor that could be significant in anticancer studies. Ki=3.7 nM.
PF-3758309, also known as PF-03758309, is a PAK4 inhibitor, is also an orally bioavailable small-molecule inhibitor of p21-activated kinase 4 (PAK4) with potent...
FRAX597 is a potent, ATP-competitive inhibitor of group I PAKs with IC50 of 8 nM, 13 nM, and 19 nM for PAK1, PAK2, and PAK3, respectively.
FRAX1036 is a highly selective PAK1 inhibitor that remarkably altered signaling to cytoskeletal-associated proteins. In vitro and in vivo tests with FRAX-1036 h...
G-5555 hydrochloride is the hydrochloride salt of G-5555 which is a potent and selective p21-activated kinase 1 (PAK1) inhibitor (Ki= 3.7 nM). G-5555 was potent...
G-5555 is a selective PAK1 Inhibitor (Ki=3.7 nM) with low clearance (CLp = 3.4 mL/min/kg) and high oral bioavailability (F = 72%). IC50: PAK2= 11 nM, SIK2= 9 mM...
IPA-3 is a selective non-ATP competitive Pak1 inhibitor with IC50 of 2.5 μM, no inhibition to group II PAKs (PAKs 4-6).
FRAX486, an effective PAK inhibitor, could improve epileptic seizures and sorts of other abnormal behaviors.
PAK4-IN-1, a substituted benzofuranyl compound, is an inhibitor of p21-activated kinases (PAKs). in MTT assay: IC50 ≤100 nM